Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study

Gabriella Ferrandina, Vanda Salutari, Bruno Vincenzi, Marco Marinaccio, Emanuele Naglieri, Vera Loizzi, Silvia Carpano, Giulia Amadio, Giuseppe Tonini, Giovanni Scambia, Domenica Lorusso

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective The aim of this multicenter, retrospective study was to evaluate the efficacy and the safety of single agent Trabectedin (ET-743, Yondelis®) in very heavily treated, relapsed ovarian cancer (ROC) patients. Patients and methods Response to treatment was classified according to RECIST criteria. Progression-free (PFS), and overall survival (OS) were also assessed. Results 98 patients were analyzed (originally 67 platinum sensitive, and 31 platinum refractory/resistant). Median number of previous regimens was 4 (range: 1-6). In the whole population, overall response rate (ORR) was 27.5%; stable disease (SD) was observed in 33 patients (33.6%), and clinical benefit was achieved in 60 cases (61.2%). ORR was 38.6% in fully platinum sensitive population, and 26.1% in partially platinum sensitive patients. In platinum refractory/resistant disease, ORR was 12.9%. Overall, median PFS and OS were 5, and 13 months, respectively. Patients responding to Trabectedin showed a more favorable PFS (median = 9 months) than patients with SD (median = 6 months), or progression (median = 2 months). Median OS of responding patients was 18 months compared to 14 months in SD patients, and 9 months in progressing patients. Grade 3-4 neutropenia was observed in 17 (17.3%) patients. Transient and non-cumulative Grade 3-4 AST and ALT level elevation was found in 7 (7.1%), and 13 (13.3%) cases, respectively. There was 1 case of Grade 3, and 1 case of Grade 4 cardiac toxicity. Conclusions Trabectedin, as a single agent, retains its efficacy in terms of rate of ORR and clinical benefit in heavily treated ROC patients, especially in the group of platinum sensitive disease.

Original languageEnglish
Pages (from-to)505-510
Number of pages6
JournalGynecologic Oncology
Volume130
Issue number3
DOIs
Publication statusPublished - Sep 2013

Fingerprint

trabectedin
Salvage Therapy
Ovarian Neoplasms
Multicenter Studies
Retrospective Studies
Platinum
Survival

Keywords

  • Ovarian cancer
  • Salvage treatment
  • Trabectedin

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients : A retrospective, multicenter study. / Ferrandina, Gabriella; Salutari, Vanda; Vincenzi, Bruno; Marinaccio, Marco; Naglieri, Emanuele; Loizzi, Vera; Carpano, Silvia; Amadio, Giulia; Tonini, Giuseppe; Scambia, Giovanni; Lorusso, Domenica.

In: Gynecologic Oncology, Vol. 130, No. 3, 09.2013, p. 505-510.

Research output: Contribution to journalArticle

Ferrandina, G, Salutari, V, Vincenzi, B, Marinaccio, M, Naglieri, E, Loizzi, V, Carpano, S, Amadio, G, Tonini, G, Scambia, G & Lorusso, D 2013, 'Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study', Gynecologic Oncology, vol. 130, no. 3, pp. 505-510. https://doi.org/10.1016/j.ygyno.2013.06.008
Ferrandina, Gabriella ; Salutari, Vanda ; Vincenzi, Bruno ; Marinaccio, Marco ; Naglieri, Emanuele ; Loizzi, Vera ; Carpano, Silvia ; Amadio, Giulia ; Tonini, Giuseppe ; Scambia, Giovanni ; Lorusso, Domenica. / Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients : A retrospective, multicenter study. In: Gynecologic Oncology. 2013 ; Vol. 130, No. 3. pp. 505-510.
@article{5dcbc515580c46b0b959f64e0d36be91,
title = "Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study",
abstract = "Objective The aim of this multicenter, retrospective study was to evaluate the efficacy and the safety of single agent Trabectedin (ET-743, Yondelis{\circledR}) in very heavily treated, relapsed ovarian cancer (ROC) patients. Patients and methods Response to treatment was classified according to RECIST criteria. Progression-free (PFS), and overall survival (OS) were also assessed. Results 98 patients were analyzed (originally 67 platinum sensitive, and 31 platinum refractory/resistant). Median number of previous regimens was 4 (range: 1-6). In the whole population, overall response rate (ORR) was 27.5{\%}; stable disease (SD) was observed in 33 patients (33.6{\%}), and clinical benefit was achieved in 60 cases (61.2{\%}). ORR was 38.6{\%} in fully platinum sensitive population, and 26.1{\%} in partially platinum sensitive patients. In platinum refractory/resistant disease, ORR was 12.9{\%}. Overall, median PFS and OS were 5, and 13 months, respectively. Patients responding to Trabectedin showed a more favorable PFS (median = 9 months) than patients with SD (median = 6 months), or progression (median = 2 months). Median OS of responding patients was 18 months compared to 14 months in SD patients, and 9 months in progressing patients. Grade 3-4 neutropenia was observed in 17 (17.3{\%}) patients. Transient and non-cumulative Grade 3-4 AST and ALT level elevation was found in 7 (7.1{\%}), and 13 (13.3{\%}) cases, respectively. There was 1 case of Grade 3, and 1 case of Grade 4 cardiac toxicity. Conclusions Trabectedin, as a single agent, retains its efficacy in terms of rate of ORR and clinical benefit in heavily treated ROC patients, especially in the group of platinum sensitive disease.",
keywords = "Ovarian cancer, Salvage treatment, Trabectedin",
author = "Gabriella Ferrandina and Vanda Salutari and Bruno Vincenzi and Marco Marinaccio and Emanuele Naglieri and Vera Loizzi and Silvia Carpano and Giulia Amadio and Giuseppe Tonini and Giovanni Scambia and Domenica Lorusso",
year = "2013",
month = "9",
doi = "10.1016/j.ygyno.2013.06.008",
language = "English",
volume = "130",
pages = "505--510",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients

T2 - A retrospective, multicenter study

AU - Ferrandina, Gabriella

AU - Salutari, Vanda

AU - Vincenzi, Bruno

AU - Marinaccio, Marco

AU - Naglieri, Emanuele

AU - Loizzi, Vera

AU - Carpano, Silvia

AU - Amadio, Giulia

AU - Tonini, Giuseppe

AU - Scambia, Giovanni

AU - Lorusso, Domenica

PY - 2013/9

Y1 - 2013/9

N2 - Objective The aim of this multicenter, retrospective study was to evaluate the efficacy and the safety of single agent Trabectedin (ET-743, Yondelis®) in very heavily treated, relapsed ovarian cancer (ROC) patients. Patients and methods Response to treatment was classified according to RECIST criteria. Progression-free (PFS), and overall survival (OS) were also assessed. Results 98 patients were analyzed (originally 67 platinum sensitive, and 31 platinum refractory/resistant). Median number of previous regimens was 4 (range: 1-6). In the whole population, overall response rate (ORR) was 27.5%; stable disease (SD) was observed in 33 patients (33.6%), and clinical benefit was achieved in 60 cases (61.2%). ORR was 38.6% in fully platinum sensitive population, and 26.1% in partially platinum sensitive patients. In platinum refractory/resistant disease, ORR was 12.9%. Overall, median PFS and OS were 5, and 13 months, respectively. Patients responding to Trabectedin showed a more favorable PFS (median = 9 months) than patients with SD (median = 6 months), or progression (median = 2 months). Median OS of responding patients was 18 months compared to 14 months in SD patients, and 9 months in progressing patients. Grade 3-4 neutropenia was observed in 17 (17.3%) patients. Transient and non-cumulative Grade 3-4 AST and ALT level elevation was found in 7 (7.1%), and 13 (13.3%) cases, respectively. There was 1 case of Grade 3, and 1 case of Grade 4 cardiac toxicity. Conclusions Trabectedin, as a single agent, retains its efficacy in terms of rate of ORR and clinical benefit in heavily treated ROC patients, especially in the group of platinum sensitive disease.

AB - Objective The aim of this multicenter, retrospective study was to evaluate the efficacy and the safety of single agent Trabectedin (ET-743, Yondelis®) in very heavily treated, relapsed ovarian cancer (ROC) patients. Patients and methods Response to treatment was classified according to RECIST criteria. Progression-free (PFS), and overall survival (OS) were also assessed. Results 98 patients were analyzed (originally 67 platinum sensitive, and 31 platinum refractory/resistant). Median number of previous regimens was 4 (range: 1-6). In the whole population, overall response rate (ORR) was 27.5%; stable disease (SD) was observed in 33 patients (33.6%), and clinical benefit was achieved in 60 cases (61.2%). ORR was 38.6% in fully platinum sensitive population, and 26.1% in partially platinum sensitive patients. In platinum refractory/resistant disease, ORR was 12.9%. Overall, median PFS and OS were 5, and 13 months, respectively. Patients responding to Trabectedin showed a more favorable PFS (median = 9 months) than patients with SD (median = 6 months), or progression (median = 2 months). Median OS of responding patients was 18 months compared to 14 months in SD patients, and 9 months in progressing patients. Grade 3-4 neutropenia was observed in 17 (17.3%) patients. Transient and non-cumulative Grade 3-4 AST and ALT level elevation was found in 7 (7.1%), and 13 (13.3%) cases, respectively. There was 1 case of Grade 3, and 1 case of Grade 4 cardiac toxicity. Conclusions Trabectedin, as a single agent, retains its efficacy in terms of rate of ORR and clinical benefit in heavily treated ROC patients, especially in the group of platinum sensitive disease.

KW - Ovarian cancer

KW - Salvage treatment

KW - Trabectedin

UR - http://www.scopus.com/inward/record.url?scp=84882449972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882449972&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2013.06.008

DO - 10.1016/j.ygyno.2013.06.008

M3 - Article

C2 - 23774301

AN - SCOPUS:84882449972

VL - 130

SP - 505

EP - 510

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -